Nicholas M Mohr1,2,3, Stephen G Pape1, Dan Runde1, Amy H Kaji4, Ron M Walls5, Calvin A Brown5. 1. From the, Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 2. the, Division of Critical Care, Department of Anesthesia, University of Iowa Carver College of Medicine, Iowa City, IA, USA. 3. the, Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA. 4. the, Department of Emergency Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 5. and the, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
OBJECTIVE: The objectives of this study were 1) to describe the current use of etomidate and other induction agents in patients with sepsis and 2) to compare adverse events between etomidate and ketamine in sepsis. METHODS: This was an observational cohort study of the prospective National Emergency Airway Registry (NEAR) data set. Descriptive statistics were used to report the distribution of induction agents used in patients with sepsis. Adverse events were compared using bivariate analysis, and a sensitivity analysis was conducted using a propensity score-adjusted analysis of etomidate versus ketamine. RESULTS: A total of 531 patients were intubated for sepsis, and the majority (71%) were intubated with etomidate as the initial induction agent. Etomidate was less frequently used in sepsis patients than nonsepsis patients (71% vs. 85%, odds ratio [OR] = 0.4, 95% confidence interval [CI] = 0.4 to 0.5). Sepsis patients had a greater risk of adverse events, and vasopressor therapy was required for 25% of patients after intubation. Postprocedure hypotension was higher between those intubated for sepsis with ketamine versus etomidate (74% vs. 50%, OR = 2.9, 95% CI = 1.9 to 4.5). After confounding by indication in the propensity score-adjusted analysis was accounted for, ketamine was associated with more postprocedure hypotension (OR = 2.7, 95% CI = 1.1 to 6.7). No difference in emergency department deaths was observed. CONCLUSIONS: Etomidate is used less frequently in sepsis patients than nonsepsis patients, with ketamine being the most frequently used alternative. Ketamine was associated with more postprocedural hypotension than etomidate. Future clinical trials are needed to determine the optimal induction agent in patients with sepsis.
OBJECTIVE: The objectives of this study were 1) to describe the current use of etomidate and other induction agents in patients with sepsis and 2) to compare adverse events between etomidate and ketamine in sepsis. METHODS: This was an observational cohort study of the prospective National Emergency Airway Registry (NEAR) data set. Descriptive statistics were used to report the distribution of induction agents used in patients with sepsis. Adverse events were compared using bivariate analysis, and a sensitivity analysis was conducted using a propensity score-adjusted analysis of etomidate versus ketamine. RESULTS: A total of 531 patients were intubated for sepsis, and the majority (71%) were intubated with etomidate as the initial induction agent. Etomidate was less frequently used in sepsis patients than nonsepsis patients (71% vs. 85%, odds ratio [OR] = 0.4, 95% confidence interval [CI] = 0.4 to 0.5). Sepsis patients had a greater risk of adverse events, and vasopressor therapy was required for 25% of patients after intubation. Postprocedure hypotension was higher between those intubated for sepsis with ketamine versus etomidate (74% vs. 50%, OR = 2.9, 95% CI = 1.9 to 4.5). After confounding by indication in the propensity score-adjusted analysis was accounted for, ketamine was associated with more postprocedure hypotension (OR = 2.7, 95% CI = 1.1 to 6.7). No difference in emergency department deaths was observed. CONCLUSIONS: Etomidate is used less frequently in sepsis patients than nonsepsis patients, with ketamine being the most frequently used alternative. Ketamine was associated with more postprocedural hypotension than etomidate. Future clinical trials are needed to determine the optimal induction agent in patients with sepsis.
Authors: Elisabeth Dewhirst; W Joshua Frazier; Marc Leder; Douglas D Fraser; Joseph D Tobias Journal: J Intensive Care Med Date: 2012-05-29 Impact factor: 3.510
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Matthew Miller; Natalie Kruit; Charlotte Heldreich; Sandra Ware; Karel Habig; Cliff Reid; Brian Burns Journal: Ann Emerg Med Date: 2016-04-27 Impact factor: 5.721
Authors: Cameron P Upchurch; Carlos G Grijalva; Stephan Russ; Sean P Collins; Matthew W Semler; Todd W Rice; Dandan Liu; Jesse M Ehrenfeld; Kevin High; Tyler W Barrett; Candace D McNaughton; Wesley H Self Journal: Ann Emerg Med Date: 2017-01 Impact factor: 5.721
Authors: Gerald Matchett; Irina Gasanova; Christina A Riccio; Dawood Nasir; Mary C Sunna; Brian J Bravenec; Omaira Azizad; Brian Farrell; Abu Minhajuddin; Jesse W Stewart; Lawrence W Liang; Tiffany Sun Moon; Pamela E Fox; Callie G Ebeling; Miakka N Smith; Devin Trousdale; Babatunde O Ogunnaike Journal: Intensive Care Med Date: 2021-12-14 Impact factor: 41.787
Authors: Garrett S Pacheco; Nicholas B Hurst; Asad E Patanwala; Cameron Hypes; Jarrod M Mosier; John C Sakles Journal: West J Emerg Med Date: 2021-02-01